Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma
NCT07203391Phase 1Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of roginolisib in Uveal melanoma (UM), sponsored by St Vincent's Hospital. Primary endpoints: Safety and tolerability of roginolisib and tebentafusp at 1 year and Maximum Tolerated Dose and Recommended Phase II Dose at 1 year. Started Feb 2026; status: recruiting.
02
Drugs
roginolisib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07203391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203391.